Abstract
Diabetes mellitus is a serious public health concern, with third world nations accounting for 80% of the new cases. Tanzania has a high diabetes burden, with rising prevalence, complications, and death, as well as life-threatening impairments. Diabetic diagnosis and prognosis are currently based on two tests: plasma glucose and glycated hemoglobin (HbA1c). However, other markers of glucose homeostasis, such as fructosamine and glycated albumin (GA), may be seen as an appealing alternative, especially in patients whose HbA1c test is skewed or incorrect. GA appears to have a higher overall diagnostic efficiency than fructosamine in a variety of clinical contexts. Further research is needed to determine whether GA can complement or replace traditional glycemic control measurements like HbA1c, as GA may aid in the therapeutic management of diabetic individuals whose HbA1c levels are unreliable.
Method A hospital-based cross-sectional analytical study design will be conducted among diabetic patients attending the diabetic clinics of the Dodoma Regional Referral Hospital and Benjamin Mkapa Hospital from 1st August to 30th October, 2023.All patients with a diagnosis of diabetes mellitus for more than 6 months on medication will be screened for eligibility. Informed consent, history and clinical examination will be obtained in all the patients. All patients will be subjected to voluntary blood sample collection and blood samples obtained will be sent for RBG and HbA1c. Simultaneously the Glycated Albumin levels will be obtained from the same blood samples collected. Standard glycemic status of all patients will be defined as per HbA1c. A level greater than 7% will be considered as a poor indicator, hence poor control in patients with more than six months of treatment. A questionnaire containing both open and closed ended questions will also be used in recording the patient’s response. Analysis including both descriptive and inferential statistics will be computed with SPSS version 28.0. and a predictor variable P<0.05 will be considered as statistically significant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study will be funded by the Ministry of Health of the United Republic of Tanzania and the funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The university of Dodoma Institutional Research Review Committee has provided its blessing to the PI's request for ethical approval through a letter with Ref No. MA.84/261/02/9.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Funding: Tanzania Ministry of Health
Competing interest: No
Data availability: Will be provided on request
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.